Newsletter | January 21, 2020

01.21.20 -- 5 Reasons External Collaborations Fail In Drug Discovery

Industry Insights
Quality Matters: SEC Analysis For Antibody Aggregates
White Paper | By Jon Lundqvist, GE Healthcare Life Sciences

Size exclusion chromatography (SEC) is the go-to analytical method in the analysis of therapeutic protein drugs. This article describes the factors affecting the reproducibility of columns and how you can minimize column variation.

A Highly Reproducible In Vivo Model For Bleomycin-Induced Lung Fibrosis In Mice To Evaluate Drugs For The Treatment Of IPF
White Paper | GVK Biosciences

Bleomycin-induced pulmonary fibrosis has been a useful pre-clinical model in several species and is most prevalent in rodent models to evaluate potential prophylactic and therapeutic drugs for IPF. 

5 Reasons External Collaborations Fail In Drug Discovery
White Paper | Dassault Systemes Americas

This white paper, brought to you by Dassault Systèmes BIOVIA, discusses the different types of external collaborations research organizations engage in, the reasons that many of these partnerships fail to meet expectations, and an informatics solutions to overcome these issues.

Softgel Technologies Overview
E-Book | Thermo Fisher Scientific

Innovative softgel technologies that maximize your market potential: Where ideation and expertise come together.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.